An observational study in Prevalence of Elevated Blood Pressure in Type-2 Diabetics, sponsored by Kabul University of Medical Sciences. Completed at 1 site in Afghanistan. Per ClinicalTrials.gov, last updated 2022-03-04.
Sponsored by Kabul University of Medical Sciences · Observational
Cardiovascular disease is the most prevalent cause of morbidity and mortality in diabetic patients. Hypertension has been confirmed as a major risk factor for cardiovascular disease, which is frequently associated with diabetes mellitus. Therefore, the detection and management of elevated blood pressure (BP) is a critical component of the comprehensive clinical management of diabetics. Since the rates of hypertension in diabetics are lacking in Afghanistan, this study aimed to evaluate the prevalence of elevated blood pressure in type-2 diabetic patients.
Cardiovascular disease is the most prevalent cause of morbidity and mortality in diabetic patients. Hypertension has been confirmed as a major risk factor for cardiovascular disease, which is frequently associated with diabetes mellitus. Therefore, the detection and management of elevated blood pressure (BP) is a critical component of the comprehensive clinical management of diabetics. Since the rates of hypertension in diabetics are lacking in Afghanistan, this study aimed to evaluate the prevalence of elevated blood pressure in type-2 diabetic patients.
This is a descriptive cross-sectional study, which included 322 type -2 diabetic patients (37 male, 63 female) who were presented to our center from November 2019 to January 2020.
6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.
This study's enrollment of 322 is close to the median of 350 across 1,163 observational studies indexed under Hypertension.
Browse Hypertension studies →Kabul University of Medical Sciences is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
All Type -2 diabetics who were presented to our center from November 2019 to January 2020.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
(37 male, 63 female)
High incidence of HTN in Diabetics
Time frame: 3 months
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Nov 2019 to primary completion in Jan 2020, 2 months.
Of 345 non-industry observational studies under Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 111. This study's 2 months is below that.
Counting every sponsor, half of 426 studies reached it within 38 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kabul University of Medical Sciences